Cargando…

Cost-utility analysis of newborn hepatitis B immunization in Beijing

OBJECTIVES: To evaluate cost-utility of universal Hepatitis B vaccination program in the Beijing city (Beijing). METHODS: A decision-Markov model was constructed to determine the cost-utility of the universal immunization program for infants (universal vaccination program) by comparing with a hypoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yiwei, Yang, Yong, Bai, Qian, Huang, Zhengwei, Wang, Zongwu, Cai, Dongxia, Li, Shuo, Man, Xiaowei, Shi, Xuefeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018439/
https://www.ncbi.nlm.nih.gov/pubmed/33016814
http://dx.doi.org/10.1080/21645515.2020.1807812
_version_ 1783674206194499584
author Guo, Yiwei
Yang, Yong
Bai, Qian
Huang, Zhengwei
Wang, Zongwu
Cai, Dongxia
Li, Shuo
Man, Xiaowei
Shi, Xuefeng
author_facet Guo, Yiwei
Yang, Yong
Bai, Qian
Huang, Zhengwei
Wang, Zongwu
Cai, Dongxia
Li, Shuo
Man, Xiaowei
Shi, Xuefeng
author_sort Guo, Yiwei
collection PubMed
description OBJECTIVES: To evaluate cost-utility of universal Hepatitis B vaccination program in the Beijing city (Beijing). METHODS: A decision-Markov model was constructed to determine the cost-utility of the universal immunization program for infants (universal vaccination program) by comparing with a hypothetic nonvaccination strategy in Beijing. Parameters in models were extracted from Beijing Center for Disease Control and Prevention (CDC) annual work report, Beijing health statistical yearbook, National Health Survey report, Beijing 1% population sample survey report, Beijing Health and Medical Price Monitoring Data Platform, and public literatures. The incremental cost‑utility ratio (ICUR) was used to compare alternative scenarios. One-way sensitivity analysis and probabilistic sensitivity analysis were used to assess parameter uncertainties. RESULTS: The universal vaccination program had increased the utility and reduced cost among infants born in 2016 in Beijing. The ICUR was CNY −24,576.61 (US$ −3779.16) per QALY for universal vaccination program comparing with non-vaccination scenario from healthcare perspective. It was estimated that the universal vaccination would save direct medical treatment cost of CNY 2,262,869,173.50 (US$ 347,962,414.43) and prevent loss of 18322.25 QALYs within lifetime of target cohort. Discount rate accounted for the most remarkable influence on ICUR in one-way sensitivity analysis. The result of probabilistic sensitivity analysis illustrated that all of the ICURs were located in the fourth quadrant of the cost-utility incremental plot undergone 5000 times of Monte Carlo simulation. CONCLUSIONS: Current universal hepatitis B vaccination program in Beijing was highly cost utility. The investment was reasonable for current universal vaccination program in Beijing.
format Online
Article
Text
id pubmed-8018439
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-80184392021-04-13 Cost-utility analysis of newborn hepatitis B immunization in Beijing Guo, Yiwei Yang, Yong Bai, Qian Huang, Zhengwei Wang, Zongwu Cai, Dongxia Li, Shuo Man, Xiaowei Shi, Xuefeng Hum Vaccin Immunother Research Paper OBJECTIVES: To evaluate cost-utility of universal Hepatitis B vaccination program in the Beijing city (Beijing). METHODS: A decision-Markov model was constructed to determine the cost-utility of the universal immunization program for infants (universal vaccination program) by comparing with a hypothetic nonvaccination strategy in Beijing. Parameters in models were extracted from Beijing Center for Disease Control and Prevention (CDC) annual work report, Beijing health statistical yearbook, National Health Survey report, Beijing 1% population sample survey report, Beijing Health and Medical Price Monitoring Data Platform, and public literatures. The incremental cost‑utility ratio (ICUR) was used to compare alternative scenarios. One-way sensitivity analysis and probabilistic sensitivity analysis were used to assess parameter uncertainties. RESULTS: The universal vaccination program had increased the utility and reduced cost among infants born in 2016 in Beijing. The ICUR was CNY −24,576.61 (US$ −3779.16) per QALY for universal vaccination program comparing with non-vaccination scenario from healthcare perspective. It was estimated that the universal vaccination would save direct medical treatment cost of CNY 2,262,869,173.50 (US$ 347,962,414.43) and prevent loss of 18322.25 QALYs within lifetime of target cohort. Discount rate accounted for the most remarkable influence on ICUR in one-way sensitivity analysis. The result of probabilistic sensitivity analysis illustrated that all of the ICURs were located in the fourth quadrant of the cost-utility incremental plot undergone 5000 times of Monte Carlo simulation. CONCLUSIONS: Current universal hepatitis B vaccination program in Beijing was highly cost utility. The investment was reasonable for current universal vaccination program in Beijing. Taylor & Francis 2020-10-05 /pmc/articles/PMC8018439/ /pubmed/33016814 http://dx.doi.org/10.1080/21645515.2020.1807812 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Research Paper
Guo, Yiwei
Yang, Yong
Bai, Qian
Huang, Zhengwei
Wang, Zongwu
Cai, Dongxia
Li, Shuo
Man, Xiaowei
Shi, Xuefeng
Cost-utility analysis of newborn hepatitis B immunization in Beijing
title Cost-utility analysis of newborn hepatitis B immunization in Beijing
title_full Cost-utility analysis of newborn hepatitis B immunization in Beijing
title_fullStr Cost-utility analysis of newborn hepatitis B immunization in Beijing
title_full_unstemmed Cost-utility analysis of newborn hepatitis B immunization in Beijing
title_short Cost-utility analysis of newborn hepatitis B immunization in Beijing
title_sort cost-utility analysis of newborn hepatitis b immunization in beijing
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018439/
https://www.ncbi.nlm.nih.gov/pubmed/33016814
http://dx.doi.org/10.1080/21645515.2020.1807812
work_keys_str_mv AT guoyiwei costutilityanalysisofnewbornhepatitisbimmunizationinbeijing
AT yangyong costutilityanalysisofnewbornhepatitisbimmunizationinbeijing
AT baiqian costutilityanalysisofnewbornhepatitisbimmunizationinbeijing
AT huangzhengwei costutilityanalysisofnewbornhepatitisbimmunizationinbeijing
AT wangzongwu costutilityanalysisofnewbornhepatitisbimmunizationinbeijing
AT caidongxia costutilityanalysisofnewbornhepatitisbimmunizationinbeijing
AT lishuo costutilityanalysisofnewbornhepatitisbimmunizationinbeijing
AT manxiaowei costutilityanalysisofnewbornhepatitisbimmunizationinbeijing
AT shixuefeng costutilityanalysisofnewbornhepatitisbimmunizationinbeijing